联合cTnT、hs-CRP、NT-ProBNP测定对心力衰竭的诊断及预后判断的意义被引量：27

下载PDF

导出

摘要目的探讨心肌肌钙蛋白T(cTnT)、高敏C反应蛋白(hs-CRP)和B型钠尿肽前体(NT-ProBNP)联合检测对心力衰竭诊断和预后判断的价值。方法测定115例明确诊断为CHF的不同病因、不同心功能分级的患者入院时、出院时血清cTnT、hs-CRP和血浆NT-ProBNP水平,进行治疗前后对比观察,并与30名健康对照组比较,随访观察患者心脏事件再发生的情况。结果血清cTnT、hs-CRP和血浆NT-ProBNP水平在CHF患者不同心功能分级组和对照组之间差异均有统计学意义,且心功能越差,其浓度越高(均P<0.01);三者在CHF患者治疗前后比较,差异均有统计学意义(均P<0.01);三者联合检测在CHF患者早期敏感性为78.3%,明显优于单项检测(均P<0.01);出院后发生心脏事件组血清cTnT、hs-CRP和血浆NT-ProBNP出院时浓度明显高于未发生心脏事件组(均P<0.01)。结论血清cTnT、hs-CRP和血浆NT-ProBNP在CHF患者中明显升高,三者联合检测对CHF临床诊断和预后判断有应用意义。

作者刘路平谢晓林林玎

机构地区杭州市第三人民医院

出处《心脑血管病防治》 2011年第1期40-42,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT

关键词肌钙蛋白T 高敏C反应蛋白 B型钠尿肽前体心力衰竭预后判断

分类号 R541.6 [医药卫生—心血管疾病] R446 [医药卫生—诊断学]

引文网络
相关文献

参考文献6

1James L,Garlos A,Saif A,et al.The N-Terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study[J].Am J Cardiol,2005,95(8):948-954.
2Pearson T,Mensah G,Alexander R,et al.Markers of inflammation and cardiovascular disease-application to clinical and public health practice:a statement for heahhcare professionals from the Centers for Disease Control and Prevention and the American Heart Assoeiation[J].Circulation,2003,107(3):499-511.
3Pfister R,Tan D,Thekkanal J,et al.Predictive value of NT-pro-BNP for the non-cardiologist.A study on 573 hospitalized patients with cardiovascular disease[J].Dtsch Med Wochenschr,2008,133(12):564-569.
4Omland T,de Lemos JA,Sabatine MS,et al.A sensitive cardiac troponin Tassay in stable coronary artery disease[J].N Engl J Med,2009,361(26):2538-2547.
5De Ferranti SD,Rifai N.C-reactive protein and cardiovascular disease:a freview of risk prediction and interventions[J].Clin Chim Acta,2002,317(1-2):1-15.
6康金锁,张春玲,于金星,丛祥凤,张健,陈曦.冠心病患者高敏C反应蛋白和NT-proBNP水平的变化[J].中华检验医学杂志,2009,32(3):300-304. 被引量：16

二级参考文献25

1史晓敏,林箐,徐国宾,宋以信,夏铁安.血清N末端B型钠尿肽原在心功能评价及慢性充血性心力衰竭诊断中的初步应用[J].中华检验医学杂志,2005,28(1):37-41. 被引量：76
2张春玲,康金锁,陈曦,张丽,张健,杨跃进,丛祥凤.心血管病患者血浆N端B型脑钠肽水平变化及其临床意义[J].中华检验医学杂志,2006,29(1):31-34. 被引量：38
3曹咏,王贤俊.糖尿病肾病与超敏C反应蛋白的关系[J].中国实验诊断学,2006,10(12):1508-1509. 被引量：2
4Taniguchi H, Momiyama Y, Ohmori R, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients in patients with stable coronary artery disease. Atherosclerosls ,2005,178 : 173-177.
5Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem,2001,47 :28-30.
6Ayash RS. High-sensitivity C-reactive protein:product claims and the Food and Drug Administration. Clin Chem, 2001,47:1743.
7Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation,2003, 107:363-369.
8Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Meal,2000, 342:836- 843.
9Lindahl B, Toss H, Siegbabn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med ,2000, 343 : 1139-1147.
10Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem,2003, 49 : 1258-1271.